Protocol Ledger

NCT06388564 · Phase II · ACTIVE NOT RECRUITING

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Interventional Phase II clinical trial protocol NCT06388564 sponsored by Incyte in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-11 Enrollment: 130 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06388564
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)130 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06388564
Protocol FieldVerified Registry Value
NCT IdentifierNCT06388564
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment130 participants (ACTUAL)
Registered Start Date2024-10-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI